Your browser doesn't support javascript.
loading
Clinical and Epidemiological Correlates of Low IFN-Gamma Responses in Mitogen Tube of QuantiFERON Assay in Tuberculosis Infection Screening During the COVID-19 Pandemic: A Population-Based Marker of COVID-19 Mortality?
Palacios-Gutiérrez, Juan-José; Rodríguez-Guardado, Azucena; Arias-Guillén, Miguel; Alonso-Arias, Rebeca; Palacios-Penedo, Sergio; García-García, José-María; Balbín, Milagros; Pérez-Hernández, Dolores; Sandoval-Torrientes, Marta; Torreblanca-Gil, Aurora; Melón, Santiago; Asensi-Álvarez, Víctor; Clain, Jeremy M; Escalante, Patricio.
Afiliação
  • Palacios-Gutiérrez JJ; Unidad de Referencia Regional de Micobacterias, AGC Laboratorio de Medicina, Hospital Universitario Central de Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA).
  • Rodríguez-Guardado A; Unidad de Enfermedades Infecciosas, Hospital Universitario de Cabueñes, Gijón, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA).
  • Arias-Guillén M; Servicio de Neumología, Hospital Universitario Central de Asturias.Facultad de Medicina, Universidad de Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA); CIBER-Enfermedades Respiratorias (ISCIII).
  • Alonso-Arias R; Servicio de Inmunología, AGC Laboratorio de Medicina, Hospital Universitario Central de Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA).
  • Palacios-Penedo S; Programa de Doctorado en Ciencias de la Salud, Universidad de Oviedo. Enfermedades Infecciosas, Departamento de Medicina, Facultad de Medicina, Universidad de Oviedo, Spain.
  • García-García JM; Servicio de Neumología, Hospital Universitario San Agustín, Avilés, Spain.
  • Balbín M; Servicio de Oncología Molecular, AGC Laboratorio de Medicina, Hospital Universitario Central de Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA); Instituto Universitario de Oncología del Principado de Asturias (IUOPA).
  • Pérez-Hernández D; Servicio de Vigilancia Epidemiológica, Dirección General de Salud Pública, Consejería de Salud Principado de Asturias, Spain.
  • Sandoval-Torrientes M; Servicio de Microbiología, AGC Laboratorio de Medicina, Hopital Universitario Central de Asturias, Oviedo, Spain.
  • Torreblanca-Gil A; Servicio de Microbiología, Hospital Universitario de Cabueñes, Gijón, Spain.
  • Melón S; Sección de Virología, Servicio de Microbiología, AGC Laboratorio de Medicina, Hospital Universitario Central de Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA).
  • Asensi-Álvarez V; Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario Central de Asturias, Facultad de Medicina, Universidad de Oviedo, Spain.
  • Clain JM; Mayo Mycobacteria and Bronchiectasis Clinic, Rochester, Minnesota, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Escalante P; Mayo Mycobacteria and Bronchiectasis Clinic, Rochester, Minnesota, USA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: Escalante.Patricio@mayo.edu.
Arch Bronconeumol ; 58(9): 649-659, 2022 Sep.
Article em En | MEDLINE | ID: mdl-35185258
ABSTRACT

Background:

The clinical and epidemiological implications of abnormal immune responses in COVID-19 for latent tuberculosis infection (LTBI) screening are unclear.

Methods:

We reviewed QuantiFERON TB Gold Plus (QFT-Plus) results (36,709 patients) from July 2016 until October 2021 in Asturias (Spain). We also studied a cohort of ninety hospitalized patients with suspected/confirmed COVID-19 pneumonia and a group of elderly hospitalized patients with COVID-19 who underwent serial QFT-Plus and immune profiling testing.

Results:

The indeterminate QFT-Plus results rate went from 1.4% (July 2016 to November 2019) to 4.2% during the COVID-19 pandemic. The evolution of the number of cases with low/very low interferon-gamma (IFN-gamma) response in the mitogen tube paralleled the disease activity and number of deaths during the pandemic waves in our region (from March 2020 to October 2021). The percentages of positive QFT-plus patients did not significantly change before and during the pandemic (13.9% vs. 12.2%). Forty-nine patients from the suspected/confirmed COVID-19 pneumonia cohort (54.4%) had low/very low IFN-gamma response to mitogen, 22 of them (24.4%) had severe and critical pneumonia. None received immunosuppressants prior to testing. Abnormal radiological findings (P = 0.01) but not COVID-19 severity was associated with low mitogen response. Immune profiling showed a reduction of CD8 + T cells and a direct correlation between the number of EMRA CD8 + T-cells and IFN-gamma response to mitogen (P = 0.03).

Conclusion:

Low IFN-gamma responses in mitogen tube of QFT-Plus often occur in COVID-19 pneumonia, which is associated with a low number of an effector CD8 + T-cell subset and does not seem to affect LTBI screening; however, this abnormality seems to parallel the dynamics of COVID-19 at the population level and its mortality.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose Latente / COVID-19 / Mycobacterium tuberculosis Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Aged / Humans Idioma: En Revista: Arch Bronconeumol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose Latente / COVID-19 / Mycobacterium tuberculosis Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Aged / Humans Idioma: En Revista: Arch Bronconeumol Ano de publicação: 2022 Tipo de documento: Article